The Gynecologic (GYN) Cancer Program has been cultivated and developed during the last 20 years and represents the largest volume center in the mid-Atlantic region. With patient-centered care and advanced research, Inova Schar Cancer Institute brings new hope and possibilities to women facing GYN cancer.

The mission of the GYN Cancer program is to provide quality care, cutting-edge therapy and diagnostics, while performing clinical and translational research to better understand how to detect, treat, and defeat GYN cancers.

Our Physicians
Larry Maxwell, MD, COL (Ret.)
Chairman, Obstetrics and Gynecology
Thomas Conrads, PhD
Associate Director, Scientific Technologies

Community Health Needs Assessment
The most recent hospital Community Needs Assessment revealed that Prince William County, located to the west of the Inova Health System primary service area, has a cervical cancer mortality rate higher than the Commonwealth of Virginia average for cervical cancer. The incidence rate of ovarian cancer in both Fairfax County and Loudoun County was higher than the Commonwealth of Virginia average from 2008-2012.

*Source: Virginia Department of Health, 2012

GYN Cancers: Total New Cases 2013 - 2017

<table>
<thead>
<tr>
<th>Year</th>
<th>Total New Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>475</td>
</tr>
<tr>
<td>2014</td>
<td>454</td>
</tr>
<tr>
<td>2015</td>
<td>530</td>
</tr>
<tr>
<td>2016</td>
<td>550</td>
</tr>
<tr>
<td>2017</td>
<td>512</td>
</tr>
</tbody>
</table>

GYN Cancers by Stage: Total New Cases 2013 - 2017

<table>
<thead>
<tr>
<th>Stage</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inova Schar Cancer Institute</td>
<td>9</td>
<td>1395</td>
<td>209</td>
<td>452</td>
<td>241</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>0%</td>
</tr>
<tr>
<td>48%</td>
</tr>
<tr>
<td>7%</td>
</tr>
<tr>
<td>16%</td>
</tr>
<tr>
<td>8%</td>
</tr>
</tbody>
</table>
GYN Prevention and Educational Programs

- An oncology therapist and nurse navigator from Life with Cancer® – the educational and emotional support program of Inova Schar Cancer Institute – participated in a Cervical Cancer Awareness program at George Mason University (GMU) on April 24, 2018. In collaboration with the National Cervical Cancer Coalition of Northern Virginia, a documentary on the HPV epidemic was viewed by 45 attendees. The program was followed by a question-and-answer session with panelists including a GMU professor of Global and Community Health as well as Life with Cancer participants.

- Life with Cancer – Fair Oaks held an educational talk, “Pelvic Floor Issues and Treatment for GYN and Breast Cancer,” on July 18, 2018. The event had 11 attendees and received positive feedback about the educational aspect of the seminar.

- Inova Schar Cancer Institute – Loudoun hosted a lecture given by Inova Translational Medicine Institute on May 19, 2018. A total of 45 women attended the seminar, “Genetics in Ovarian and Breast Cancers,” which was part of a series of education programs held in conjunction with the opening of the Inova Schar Cancer Institute Peterson Family Breast Center.

- Inova Schar Cancer Institute – Alexandria hosted three “Ladies’ Night Out” events with after-hours discounted mammograms on May 16, October 11, and October 24, 2018. Packets of educational materials on women’s cancers were distributed to all participants. Inova Alexandria Hospital continues to educate the women of Alexandria regarding other women’s cancers including uterine, ovarian and cervical.

2018 Clinical Trials

The following GYN Cancer trials were available to patients at Inova Schar Cancer Institute in 2018.

*Note: Some trials may now be closed to enrollment.*

**CT.GOV ID: NCT02839707** Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. (PI: Maitland)

**CT.GOV ID: NCT02983799** Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy – Astra Zeneca. (PI: Maitland)

**CT.GOV ID: NCT02635360** A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer. (PI: Maxwell)

**CT.GOV ID: NCT02465060** NCI MATCH Molecular Analysis for Therapy Choice. (PI: Deeken)

**CT.GOV ID: NCT02693535** The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (PI: Cannon)

GYN Screening Program

On September 28, 2018 Inova Schar Cancer Institute – Fair Oaks hosted a community GYN Cancer screening at no cost to attendees. Volunteers were comprised of five physicians and 16 support staff, including clinical nurse midwives, nurse practitioners, registered nurses, administrative staff and interpreters.

A total of 34 patients received a GYN Cancer screening via Pap test. The results are as follows: 30 negative, three positive, and one with no lab testing necessary. The three positive results were referred for further follow-up with a physician, and three patients were referred for a sonogram or colonoscopy.